nach oben

Current Breast Cancer Reports

Erschienen in:

03.04.2018 | Local-Regional Evaluation and Therapy (DM Euhus, Section Editor)

Recent Trends in Local-Regional Recurrence Rates: Implications for Therapeutic Intervention

verfasst von: Vishnu Prasath, Mehran Habibi

Erschienen in: Current Breast Cancer Reports | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Local and regional recurrences pose a significant therapeutic challenge in the field of breast cancer. Unfortunately, between 5 and 10% of patients will have this form of recurrences. This article seeks to review recent declines in locoregional recurrence risk and discuss the potential implications for the extent of therapeutic intervention currently implemented and how this may change in the future.

Recent Findings

Recurrence rates have significantly decreased in recent times. Additionally, the vast amount of clinical research in the field of breast cancer allows for guidelines and traditional treatments to be updated and revamped as novel information is discovered. Patients who had neoadjuvant chemotherapy have been shown to experience a higher rate of recurrence in comparison with patients that had adjuvant chemotherapy. Radiotherapy is now recommended for patients with one to three positive lymph nodes. Axillary resections have been shown to provide no benefits to patients undergoing radiotherapy.

Summary

Local and regional recurrence rates are decreasing lately both due to improvements in various therapeutic interventions and in implementation of breast cancer screening so that cancers may be caught earlier. Due to declines in local recurrence risk, it may be reasonable to scale back surgical, chemotherapeutic, and radio-therapeutic interventions.

• Euhus DM. New insights into the surgical management of breast cancer. Semin Radiat Oncol. 2016;26:25–36. This comprehensive review article discusses novel findings across the field of surgical intervention for breast cancer. CrossRefPubMed

Bouganim N, Tsvetkova E, Clemons M, Amir E. Evolution of sites of recurrence after early breast cancer over the last 20 years: implications for patient care and future research. Breast Cancer Res Treat. 2013;139:603–6.CrossRefPubMed

Jobsen J, van der Palen J, Riemersma S, Heijmans H, Ong F, Struikmans H. Pattern of ipsilateral breast tumor recurrence after breast-conserving therapy. Int J Radiat Oncol Biol Phys. 2014;89:1006–14.CrossRefPubMed

Canavan J, Truong PT, Smith SL, Lu L, Lesperance M, Olivotto IA. Local recurrence in women with stage I breast cancer: declining rates over time in a large, population-based cohort. Int J Radiat Oncol. 2014;88:80–6.CrossRef

Çelik, V., Aydoğan, T., Yilmaz, M. H., Yaşar, N. F. & Müslümanoğlu, M. Surveillance of patients following primary therapy. in Breast Disease. 2016;447–54. Springer, Cham

Voogd AC, Nielsen M, Peterse JL, Blichert-Toft M, Bartelink H, Overgaard M, et al. Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. J Clin Oncol. 2001;19:1688–97.CrossRefPubMed

van Tienhoven G, Voogd AC, Peterse JL, Nielsen M, Andersen KW, Mignolet F, et al. Prognosis after treatment for loco-regional recurrence after mastectomy or breast conserving therapy in two randomised trials (EORTC 10801 and DBCG-82TM). Eur J Cancer. 1999;35:32–8.CrossRefPubMed

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials. Lancet. 2011;378:1707–16.CrossRef

Okamura H, Yamamoto N, Watanabe T, Katsumata N, Takashima S, Adachi I, et al. Psychological distress following first recurrence of disease in patients with breast cancer: prevalence and risk factors. Breast Cancer Res Treat. 2000;61:131–7.CrossRefPubMed

10.

Plasilova ML, Hayse B, Killelea BK, Horowitz NR, Chagpar AB, Lannin DR. Features of triple-negative breast cancer: analysis of 38,813 cases from the national cancer database. Medicine (Baltimore). 2016;95:e4614.CrossRef

11.

Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13:4429–34.CrossRefPubMed

12.

Voduc KD, Cheang MCU, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol. 2010;28:1684–91.CrossRefPubMed

13.

Subhedar P, Olcese C, Patil S, Morrow M, Van Zee KJ. Decreasing recurrence rates for ductal carcinoma in situ: analysis of 2996 women treated with breast-conserving surgery over 30 years. Ann Surg Oncol. 2015;22:3273–81.CrossRefPubMedPubMedCentral

14.

Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast Cancer. J Clin Oncol. 2003;21:976–83.CrossRefPubMed

15.

Dahabreh IJ, Linardou H, Siannis F, Fountzilas G, Murray S. Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials. Oncologist. 2008;13:620–30.CrossRefPubMed

16.

Fisher B, Jeong J-H, Anderson S, Wolmark N. Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: updated findings from National Surgical Adjuvant Breast and Bowel Project Clinical Trials. JNCI J Natl Cancer Inst. 2004;96:1823–31.CrossRefPubMed

17.

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–717.CrossRef

18.

Malmgren JA, Parikh J, Atwood MK, Kaplan HG. Impact of mammography detection on the course of breast cancer in women aged 40–49 years. Radiology. 2012;262:797–806.CrossRefPubMed

19.

Lupe K, Truong PT, Alexander C, Lesperance M, Speers C, Tyldesley S. Subsets of women with close or positive margins after breast-conserving surgery with high local recurrence risk despite breast plus boost radiotherapy. Int J Radiat Oncol. 2011;81:e561–8.CrossRef

20.

Botteri E, Bagnardi V, Rotmensz N, Gentilini O, Disalvatore D, Bazolli B, et al. Analysis of local and regional recurrences in breast cancer after conservative surgery. Ann Oncol Off J Eur Soc Med Oncol. 2010;21:723–8.CrossRef

21.

Houssami N, Macaskill P, Luke Marinovich M, Morrow M. The association of surgical margins and local recurrence in women with early-stage invasive breast cancer treated with breast-conserving therapy: a meta-analysis. Ann Surg Oncol. 2014;21:717–30.CrossRefPubMedPubMedCentral

22.

Wapnir IL, Anderson SJ, Mamounas EP, Geyer CE Jr, Jeong JH, Tan-Chiu E, et al. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials. J Clin Oncol. 2006;24:2028–37.CrossRefPubMed

23.

Anderson SJ, Wapnir I, Dignam JJ, Fisher B, Mamounas EP, Jeong JH, et al. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer. J Clin Oncol. 2009;27:2466–73.CrossRefPubMedPubMedCentral

24.

Miles RC, Gullerud RE, Lohse CM, Jakub JW, Degnim AC, Boughey JC. Local recurrence after breast-conserving surgery: multivariable analysis of risk factors and the impact of young age. Ann Surg Oncol. 2012;19:1153.

25.

van Roozendaal LM, Smit LHM, Duijsens GHNM, de Vries B, Siesling S, Lobbes MBI, et al. Risk of regional recurrence in triple-negative breast cancer patients: a Dutch cohort study. Breast Cancer Res Treat. 2016;156:465–72.CrossRefPubMedPubMedCentral

26.

Hattangadi-Gluth JA, Wo JY, Nguyen PL, Abi Raad RF, Sreedhara M, Niemierko A, et al. Basal subtype of invasive breast cancer is associated with a higher risk of true recurrence after conventional breast-conserving therapy. Int J Radiat Oncol Biol Phys. 2012;82:1185–91.CrossRefPubMed

27.

Nilsson MP, Hartman L, Kristoffersson U, Johannsson OT, Borg Å, Henriksson K, et al. High risk of in-breast tumor recurrence after BRCA1/2-associated breast cancer. Breast Cancer Res Treat. 2014;147:571–8.CrossRefPubMedPubMedCentral

28.

•• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol. 2018;19:27–39. This recent study reported that neoadjuvant chemotherapy was associated with more frequent local recurrence than adjuvant chemotherapy. CrossRef

29.

Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis. JAMA. 2011;305:569–75.CrossRefPubMedPubMedCentral

30.

• Giuliano AE, Ballman KV, McCall L, Beitsch PD, Brennan MB, Kelemen PR, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis. JAMA. 2017;318:918–26. This study reports on the Z011 trial in which the effects of axillary lymph node dissection was investigated. CrossRefPubMedPubMedCentral

31.

Donker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde CJH, Mansel RE, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet. Oncol. 2014;15:1303–10.CrossRefPubMedPubMedCentral

32.

•• Mamounas EP, Liu Q, Paik S, Baehner FL, Tang G, Jeong JH, et al. 21-Gene recurrence score and locoregional recurrence in node-positive/ER-positive breast cancer treated with chemo-endocrine therapy. J Natl Cancer Inst. 2017;109:djw259. This study reports on the B-28 trial used to study the Oncotype-Dx expression assay. CrossRefPubMedPubMedCentral

33.

•• Cardoso F, van’t Veer L, Bogaerts J, Slaets L, Viale G, Delaloge S, et al. 70-Gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med. 2016;375:717–29. This study reports on the MINDACT trial used to study the Mammaprint recurrence score assay. CrossRefPubMed

34.

Mamounas EP, Tang G, Fisher B, Paik S, Shak S, Costantino JP, et al. Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. J Clin Oncol. 2010;28:1677–83.CrossRefPubMedPubMedCentral

35.

Győrffy B, Hatzis C, Sanft T, Hofstatter E, Aktas B, Pusztai L. Multigene prognostic tests in breast cancer: past, present, future. Breast Cancer Res. 2015;17:11.CrossRefPubMedPubMedCentral

36.

Whelan TJ, Olivotto IA, Parulekar WR, Ackerman I, Chua BH, Nabid A, et al. Regional nodal irradiation in early-stage breast cancer. N Engl J Med. 2015;373:307–16.CrossRefPubMedPubMedCentral

37.

Akhtari M, Teh BS. Accelerated partial breast irradiation: advances and controversies. Chin J Cancer. 2016;35:31.CrossRefPubMedPubMedCentral

38.

Polgár C, Fodor J, Major T, Németh G, Lövey K, Orosz Z, et al. Breast-conserving treatment with partial or whole breast irradiation for low-risk invasive breast carcinoma—5-year results of a randomized trial. Int. J. Radiat. Oncol. 2007;69:694–702.CrossRef

39.

• Yao K, Czechura T, Liederbach E, Winchester DJ, Pesce C, Shaikh A, et al. Utilization of accelerated partial breast irradiation for ductal carcinoma in situ, 2003–2011: report from the National Cancer Database. Ann Surg Oncol. 2014;21:3457–65. This study discusses the trends in usage of Accelerated Partial Breast Irradiation and that facility factors were most strongly associated with its use. CrossRefPubMed

40.

• EBCTCG (Early Breast Cancer Trialists’ Collaborative Group). Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 2014;383:2127–35. This study reported that radiotherapy decreases local and regional recurrence rates in the population of patients with one to three positive lymph nodes. CrossRef

41.

Bazan JG, White JR. The role of postmastectomy radiation therapy in patients with breast cancer responding to neoadjuvant chemotherapy. Semin Radiat Oncol. 2016;26:51–8.CrossRefPubMed

42.

Kishan AU, McCloskey SA. Postmastectomy radiation therapy after neoadjuvant chemotherapy: review and interpretation of available data. Ther Adv Med Oncol. 2016;8:85–97.CrossRefPubMedPubMedCentral

43.

Neuman HB, Schumacher JR, Francescatti AB, Adesoye T, Edge SB, Vanness DJ, et al. Risk of synchronous distant recurrence at time of locoregional recurrence in patients with stage II and III breast cancer (AFT-01). J Clin Oncol. JCO2017755389 (2018). https://doi.org/10.1200/JCO.2017.75.5389 (epub ahead of print).

44.

Newman EA, Cimmino VM, Sabel MS, Diehl KM, Frey KA, Chang AE, et al. Lymphatic mapping and sentinel lymph node biopsy for patients with local recurrence after breast-conservation therapy. Ann Surg Oncol. 2006;13:52–7.CrossRefPubMed

45.

Intra M, Trifirò G, Viale G, Rotmensz N, Gentilini OD, Soteldo J, et al. Second biopsy of axillary sentinel lymph node for reappearing breast cancer after previous sentinel lymph node biopsy. Ann Surg Oncol. 2005;12:895–9.CrossRefPubMed

46.

Marta GN, Hijal T, de Andrade Carvalho H. Reirradiation for locally recurrent breast cancer. Breast. 2017;33:159–65.CrossRefPubMed

47.

Wahl AO & Small W Re-irradiation for locally recurrent breast cancer. Medical Radiology. 2016;213–24. Springer, Cham

48.

Ishitobi M, Okumura Y, Nishimura R, Nakatsukasa K, Tanabe M, Yoshida A, et al. Repeat lumpectomy for ipsilateral breast tumor recurrence (IBTR) after breast-conserving surgery: the impact of radiotherapy on second IBTR. Breast Cancer. 2014;21:754–60.

49.

Jolicoeur M, David S, Rousseau P, Mondat M. Long-term follow-up for high-dose-rate interstitial brachytherapy and lumpectomy as a second conservative treatment for local recurrences of breast cancer. Int. J. Radiat. Oncol. 2017;99:S6.CrossRef

50.

Yoshida A, Takahashi O, Okumura Y, Arima N, Nakatsukasa K, Tanabe M, et al. Prognosis after mastectomy versus repeat lumpectomy in patients with ipsilateral breast cancer recurrence: a propensity score analysis. Eur J Surg Oncol. 2016;42:474–80.CrossRefPubMed

51.

Aebi S, Gelber S, Anderson SJ, Láng I, Robidoux A, Martín M, et al. Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial. Lancet Oncol. 2014;15:156–63.CrossRefPubMedPubMedCentral

52.

Allison RR, Sibata C, Mang TS, Bagnato VS, Downie GH, Hu XH, et al. Photodynamic therapy for chest wall recurrence from breast cancer. Photodiagn Photodyn Ther. 2004;1:157–71.CrossRef

53.

Campana LG, Valpione S, Falci C, Mocellin S, Basso M, Corti L, et al. The activity and safety of electrochemotherapy in persistent chest wall recurrence from breast cancer after mastectomy: a phase-II study. Breast Cancer Res Treat. 2012;134:1169–78.CrossRefPubMed

Titel: Recent Trends in Local-Regional Recurrence Rates: Implications for Therapeutic Intervention
verfasst von: Vishnu Prasath
Mehran Habibi
Publikationsdatum: 03.04.2018
Verlag: Springer US
Erschienen in: Current Breast Cancer Reports / Ausgabe 2/2018
Print ISSN: 1943-4588
Elektronische ISSN: 1943-4596
DOI: https://doi.org/10.1007/s12609-018-0270-2

Neu im Fachgebiet Onkologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Recent Trends in Local-Regional Recurrence Rates: Implications for Therapeutic Intervention

Abstract

Purpose of Review

Recent Findings

Summary

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2018

Prepectoral Breast Reconstruction

Breast Density and the Importance of Supplemental Screening

Immunotherapy in Breast Cancer: the New Frontier

Estimating Contralateral Breast Cancer Risk

HER2 Activating Mutations in Estrogen Receptor Positive Breast Cancer

Choosing Wisely: Optimizing Routine Workup for the Newly Diagnosed Breast Cancer Patient

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie